Production (Stage)
BioSyent Inc.
RX.V
TSX
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 33.36% | 3.33% | 5.93% | 10.28% | 19.68% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 33.36% | 3.33% | 5.93% | 10.28% | 19.68% |
| Cost of Revenue | 56.10% | 1.68% | 12.51% | 25.46% | 38.94% |
| Gross Profit | 27.48% | 3.72% | 4.25% | 6.85% | 15.54% |
| SG&A Expenses | 23.88% | 85.35% | 9.37% | 6.37% | 3.54% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 32.95% | 89.54% | 10.30% | 10.87% | 11.55% |
| Operating Income | 34.47% | 182.21% | -3.59% | 8.17% | 49.04% |
| Income Before Tax | 23.22% | 17.95% | -4.45% | 4.60% | 50.98% |
| Income Tax Expenses | 23.21% | 53.45% | -7.75% | 4.60% | 50.97% |
| Earnings from Continuing Operations | 23.22% | 8.06% | -3.46% | 4.60% | 50.98% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 23.22% | 8.06% | -3.46% | 4.60% | 50.98% |
| EBIT | 34.47% | 182.21% | -3.59% | 8.17% | 49.04% |
| EBITDA | 34.83% | 200.59% | -4.99% | 6.51% | 45.80% |
| EPS Basic | 27.47% | 10.84% | -1.35% | 8.85% | 56.69% |
| Normalized Basic EPS | 27.62% | 165.24% | -2.32% | 8.87% | 56.46% |
| EPS Diluted | 26.79% | 10.92% | -1.65% | 8.66% | 57.41% |
| Normalized Diluted EPS | 27.02% | 164.79% | -2.62% | 8.89% | 56.93% |
| Average Basic Shares Outstanding | -3.40% | -2.58% | -2.16% | -3.88% | -3.56% |
| Average Diluted Shares Outstanding | -2.99% | -2.46% | -1.94% | -3.94% | -3.82% |
| Dividend Per Share | 4.19% | 9.18% | 10.74% | 10.40% | 12.84% |
| Payout Ratio | -0.18% | -0.02% | 0.12% | 0.01% | -0.28% |